ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tenofovir amibufenamide

Also written as “HS-10234”, “Tenofovir Amibufenamide(TMF)” and “Tenofovir Amibufenamide(TMF)”.

Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.

Furthest: phase 4, since Dec 13, 20244 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group31 open or runningphase 4since Dec 13, 2024Mar 3, 2019none ahead
GNI Groupits history only10 open or runningphase 1since Dec 10, 2025Dec 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2019First study: phase 3 study in Chronic HBV InfectionFirst studyNCT03903796 · 963 enrolled · China
  2. Jun 9, 2020Named tenofovir amibufenamideINNProposed as its International Nonproprietary Name in WHO's List 123 · before, HS-10234
  3. Jul 14, 2020Phase 1 study in Healthy SubjectsNCT04477096 · 36 enrolled · China
  4. Dec 13, 2024Phase 4 study in Hepatitis B, ChronicNCT06743438 · 640 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06743438Hepatitis B, Chronic · China4Active, not recruitingJun 30, 2024640
NCT04477096Healthy Subjects · China1CompletedSep 24, 202036
NCT03903796Chronic HBV Infection · China3CompletedMay 31, 2020963

How it is read

Names in the registry

  • “HS-10234”, 2 entries
  • “Tenofovir Amibufenamide(TMF)”, 1 entry
  • “Tenofovir Amibufenamide(TMF)”, 1 entry

Codes read as this program: HS10234.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.